Skip to main content

Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study”

A Letter to the Editor to this article was published on 27 October 2021

The Original Research Article was published on 30 March 2021

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Borg E, Thoning H. Comment on: “Drug survival of IL-12/23, IL- 17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi‑country, multicentric cohort study.” Am J Clin Dermatol. 2021. https://doi.org/10.1007/s40257-021-00642-3

    Article  PubMed  Google Scholar 

  2. 2.

    Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–79.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tiago Torres.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this letter.

Conflicts of interest/competing interest

T. Torres has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, and Sanofi. A. Chiricozzi has served as advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme, and UCB Pharma. L. Puig has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, and Sandoz.

Availability of data and material

Not applicable.

Ethics approval

Not applicable.

Consent

Not applicable.

Author contributions

TT, AC and LP provided critical feedback on the manuscript, approved the final manuscript for submission, and were accountable for the accuracy and integrity of the article.

Additional information

Additional information

This reply refers to the comment available at: https://doi.org/10.1007/s40257-021-00642-3.

This reply refers to the article available at: https://doi.org/10.1007/s40257-021-00598-4.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Torres, T., Chiricozzi, A. & Puig, L. Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study”. Am J Clin Dermatol 22, 903–904 (2021). https://doi.org/10.1007/s40257-021-00640-5

Download citation